JSRAX
Price
$17.06
Change
+$0.02 (+0.12%)
Updated
Jun 12 closing price
Net Assets
1.83B
NWESX
Price
$7.86
Change
+$0.02 (+0.26%)
Updated
Jun 12 closing price
Net Assets
203.6M
Interact to see
Advertisement

JSRAX vs NWESX

Header iconJSRAX vs NWESX Comparison
Open Charts JSRAX vs NWESXBanner chart's image
JSRAX vs NWESX Comparison Chart in %
View a ticker or compare two or three
VS
JSRAX vs. NWESX commentary
Jun 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JSRAX is a Hold and NWESX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JSRAX has more cash in the bank: 1.83B vs. NWESX (204M). NWESX pays higher dividends than JSRAX: NWESX (3.65) vs JSRAX (2.97). JSRAX was incepted earlier than NWESX: JSRAX (20 years) vs NWESX (19 years). JSRAX (0.88) is less costly to investors than NWESX (0.71). NWESX is a more actively managed with annual turnover of: 31.55 vs. JSRAX (12.00). JSRAX has a lower initial minimum investment than NWESX: JSRAX (500) vs NWESX (50000). NWESX annual gain was more profitable for investors over the last year : 11.94 vs. JSRAX (9.84). JSRAX return over 5 years is better than : 8.71 vs. NWESX (1.85).
JSRAXNWESXJSRAX / NWESX
Total Expense Ratio0.690.7197%
Annual Report Gross Expense Ratio0.880.71124%
Fund Existence20 years19 years-
Gain YTD4.2154.59292%
Front Load5%N/A-
Min. Initial Investment500500001%
Min. Initial Investment IRAN/AN/A-
Net Assets1.83B204M895%
Annual Yield % from dividends2.973.6581%
Returns for 1 year9.8411.9482%
Returns for 3 years30.6320.45150%
Returns for 5 years8.711.85471%
Returns for 10 years27.7724.06115%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALLY44.370.88
+2.02%
Ally Financial
PKOH34.730.63
+1.85%
Park-Ohio Holdings Corp
LGO0.80N/A
N/A
Largo
TMDX72.91-0.68
-0.92%
TransMedics Group
BDRX3.03-0.05
-1.69%
Biodexa Pharmaceuticals plc